results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
Published 1 year ago • 63 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
2:05
updated phase i results from sgnbcma-001 study of sea-bcma in patients with r/r multiple myeloma
-
2:29
phase i first-in-human study of alnuctamab in patients with r/r multiple myeloma
-
2:42
results from a phase i study of cc-98633 in r/r myeloma
-
12:17
updated iv and sc results from a phase i dose escalation study of forimtamig with rrmm patients
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
4:58
findings of a phase i study of anitocabtagene autoleucel for the treatment of r/r myeloma
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
1:56
updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
-
1:28:45
understanding your lab results (2018)
-
24:46
sumit verma of iovance biotherapeutics - 1 time therapy for solid tumors
-
1:00:21
units of life: lindsay case, protein phase separation regulates transmembrane signaling (2021)
-
1:29
initial results of the phase iii boston study
-
4:38
results of phase ib/ii study of ricolinostat in multiple myeloma
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
5:46
determination: results & implications in clinical practice
-
1:25
preliminary results from a phase ib trial of as-1763, a novel non-covalent btki, in cll/mcl
-
5:41
primary results from the phase iii shine study: ibrutinib br for older patients with mcl
-
8:05
interim phase 1b study results on isatuximab and pd subcutaneous administration in rrmm patients
-
58:13
optimising transplant outcome in adults allografted for aml
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
0:47
overview of the phase iii enhance trial schema